Randomized Controlled Trials in Neuroendocrine Tumors

John C McAuliffe; Edward M Wolin

doi:10.1016/j.soc.2017.05.012

Randomized Controlled Trials in Neuroendocrine Tumors

Surg Oncol Clin N Am. 2017 Oct;26(4):751-765. doi: 10.1016/j.soc.2017.05.012. Epub 2017 Aug 4.

Authors

John C McAuliffe¹, Edward M Wolin²

Affiliations

¹ Department of Surgery, Montefiore-Einstein Center for Cancer Care, 1521 Jarrett Place, Suite 207, Bronx, NY 10461, USA.
² Neuroendocrine Tumor Program, Division of Medical Oncology, Department of Medicine, Montefiore-Einstein Center for Cancer Care, 1695 Eastchester Road, 2nd Floor, Bronx, NY 10461, USA. Electronic address: ewolin@montefiore.org.

PMID: 28923229
DOI: 10.1016/j.soc.2017.05.012

Abstract

Understanding of neuroendocrine tumors has increased greatly in the last 2 decades. Along with this, the prevalence of neuroendocrine tumors has increased because of the ubiquitous use of cross-sectional imaging, improved endoscopic screening, and the indolent nature of the disease. Up to 35% of patients have symptoms at the time of diagnosis, whereas the others have occult disease. Neuroendocrine tumors are a diverse group of malignancies with unique clinical courses. This article critically reviews the most important randomized controlled trials for neuroendocrine tumors and introduces a few awaiting completion.

Keywords: Carcinoid; Clinical trial; Neuroendocrine tumor; Somatostatin.

Publication types

Review

MeSH terms

Humans
Neuroendocrine Tumors / diagnosis*
Neuroendocrine Tumors / therapy*
Randomized Controlled Trials as Topic*